Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Medigap Plans In Illinois To Benefit From Medicare Advantage Reimbursement Cuts
HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that planned cuts to Medicare Advantage reimbursement will benefit organizations offering Medicare supplement plans in Illinois. According to the recent Illinois Health Plan Analysis, the shift from Medicare Advantage to Medicare supplement plans, also known as Medigap plans, will likely benefit Blue Cross Blue Shield of Illinois, the state"s top Medigap insurer.
generic viagra online
Tiller Murder Increases Tension Over 'Common Ground' Approach To Abortion-Rights Debate
The recent murder of Kansas abortion provider George Tiller has increased tensions between groups on both sides of the abortion debate at a time when the White House is advocating a move toward "common ground" on the issue, the Los Angeles Times reports. Tiller, one of the few doctors who performed abortions later in pregnancy, was shot to death in his church on Sunday. According to the Times, some advocates feel that the murder will further complicate the Obama administration"s efforts to find areas for agreement in the abortion-rights debate. Abortion-rights advocate Cristina Page -- an author and blogger who attended initial White House meetings on forming effective reproductive health policies -- called Tiller"s death a "massive setback" to the idea of finding common ground with abortion-rights opponents. She added that it is "sort of like having a family member murdered and then being asked to make nice with the assassin"s family. It"s unnatural." However, some antiabortion-rights groups say that President Obama"s policy moves, such as his proposal to rescind the Bush administration"s provider "conscience" rule, have undercut his calls for compromise. Marjorie Dannenfelser, president of the Susan B. Anthony List, said, "It is very hard to find common ground when none of your policies overlap with the people you are trying to find common ground with."The Obama administration in the coming months plans to continue meetings with advocates on both sides of the abortion debate as it drafts policy proposals aimed at preventing unintended pregnancies and reducing the need for abortion, the Times reports. According to the Times, one area of debate that arose after the first meeting was the White House"s distinction between reducing the need for abortion versus some antiabortion-rights advocates" focus on reducing the number of abortions. After the meeting, Wendy Wright, president of the antiabortion-group Concerned Women for America, blogged that she disagreed with abortion-rights advocates" objections to the phrase "reducing abortions." Page said that Wright seemed to aim to start a fight over words to impede discussion. "We"ve gotten dragged very quickly, by [Wright], back to the same debate that we"ve all suffered through for 36 years," Page said. Nancy Northup, president of the Center for Reproductive Rights, said that the "issue should be reducing the number of unintended pregnancies." Melody Barnes, head of Obama"s Domestic Policy Council, said in an interview in May that the White House"s "goal is to reduce the need for abortions.÷ ... If people have better access to contraception, that"s a way of addressing the issue at its root, rather than do a tally of abortions" (Wallsten/Abcarian, Los Angeles Times, 6/3).
News of the day
22nd Congress Of The European College Of Neuropsychopharmacology
The 22nd Congress of the European College of Neuropsychopharmacology (ECNP) will be held from 12-16 September 2009 in Istanbul, Turkey.
Endocrinology

Onset Therapeutics Launches HYLATOPIC™ Emollient Foam For Atopic Dermatitis

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, announced the FDA approval and commercial launch of HYLATOPIC™ Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis. HYLATOPIC™ Emollient Foam is formulated to rapidly hydrate the stratum corneum, the top layer of the skin, and immediately provide a semi-permeable barrier that protects against irritants and excessive water loss through the epidermis. HYLATOPIC™ is clinically proven to rapidly increase skin hydration and reduce transepidermal water loss1, supporting the skin"s natural recovery from skin barrier dysfunction to optimize therapeutic outcomes. HYLATOPIC™ is safe and easy to spread over large areas and therefore is ideal for atopic dermatitis patients with disease coverage on greater than 10% body surface area (BSA). The Company"s recent market research with dermatologists indicates that 70% or more of their patients may have atopic dermatitis present on at least 10% of their body. Developed with the Company"s DELEVO™ Foam Technology, HYLATOPIC™ is cosmetically elegant, contains no drying alcohols, is absorbed rapidly, and leaves no oily or sticky residue. "We are very excited to be able to offer HYLATOPIC™ to our physicians and patients," states Michael Heffernan, President of Onset Therapeutics. "It is well known that skin barrier dysfunction is a fundamental problem in atopic dermatitis patients. HYLATOPIC"s 3-step approach to hydrate, protect and restore the natural skin barrier, combined with the aesthetic and safety elements which drive compliance, assists in helping our physicians achieve the best therapeutic outcomes." HYLATOPIC™ Emollient Foam is currently available through all major drug wholesalers. About Atopic Dermatitis Atopic dermatitis is a disease characterized by dry, cracked, itchy, and inflamed skin, often presenting on greater than 10% of the body surface area. It accounts for 10-20% of all Dermatology visits2 and affects approximately 3% of the US population2, 90% of whom develop symptoms by age 53. The compromised skin barrier in atopic dermatitis patients allows excessive water loss through the epidermal layer of the skin and penetration of potential allergens. About Onset Therapeutics Onset Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of dermatology products formulated with the Company"s innovative proprietary topical formulation technologies and unique delivery systems. The Company utilizes its novel DELEVO™ Foam Technology that is designed to deliver enhanced penetration of proven active ingredients in cosmetically elegant, hydrating formulations with the goal of enhancing patient compliance. For more information, please visit the company"s website at http://www.onsettx.com. References: 1. Data on File Collegium Pharmaceutical 2. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Available at: http://www.niams.nih.gov/hi/topics/dermatitis/index.html. 3. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351:1715-1721. Onset Therapeutics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009